Clinical Trial Update: A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children [Phase 2]

View source ↗

Summary

Phase 2 trial investigating mepolizumab as adjunctive therapy to prevent asthma exacerbations in urban children; study completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Mepolizumab (mepolizumab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Asthma | Phase 2 | Status: COMPLETED | Results posted: 2022-06-21